Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000083.xml
Download PDF
Synlett 2019; 30(03): 303-306
DOI: 10.1055/s-0037-1611957
DOI: 10.1055/s-0037-1611957
letter
Synthesis of 5-Aryl-5H-pyrido[2',1':2,3]imidazo[4,5-b]indoles by Domino Pd- and Cu-Catalyzed C–N Coupling Reactions
This research is funded by the Vietnam National Foundation for Science and Technology Development (NAFOSTED) under grant number 104.012015.81.
Further Information
Publication History
Received: 02 November 2018
Accepted after revision: 09 December 2018
Publication Date:
10 January 2019 (online)
Abstract
A series of 5-aryl-5H-pyrido[2',1':2,3]imidazo[4,5-b]indoles was successfully prepared in good yields by a practical four-step strategy. In this procedure, the key step was demonstrated to be the domino Pd-and Cu-catalyzed C–N coupling reactions of 3-bromo-2-(2-bromophenyl)imidazo[1,2-a]pyridine with amines.
Supporting Information
- Supporting information for this article is available online at https://doi.org/10.1055/s-0037-1611957.
- Supporting Information
-
References and Notes
- 1 Sabir S, Alhazza MI, Ibrahim AA. Catal. Sustain. Energy 2016; 2: 99
- 2 Vardanyan R, Hruby V. Synthesis of Best-Seller Drugs . Elsevier; London, UK: 2016: 868
- 3 Tabassum K, Ekta P, Kavitkumar P. Mini-Rev. Org. Chem. 2018; 15: 459
- 4 Sellamuthu S, Gutti G, Kumar D, Kumar Singh S. Mini-Rev. Org. Chem. 2018; 15: 498
- 5 Carril M, SanMartin R, Domínguez E, Tellitu I. Green Chem. 2007; 9: 219
- 6 Butera JA, Antane SA, Hirth B, Lennox JR, Sheldon JH, Norton NW, Warga D, Argentieri TM. Bioorg. Med. Chem. Lett. 2001; 11: 2093
- 7 Sui Z, Zhang X, Li X. PCT Int. Appl. 2006116513, 2006
- 8 Kim Y.-C, Park C.-S, Ha T.-S. PCT Int. Appl. WO 2006096030A, 2006
- 9 Gormemis AE, Ha TS, Im I, Jung K.-Y, Lee JY, Park C.-S, Kim Y.-C. ChemBioChem 2005; 6: 1745
- 10 Langer SZ, Arbilla S, Benavides J, Scatton B. Adv. Biochem. Psychopharmacol. 1990; 46: 61
- 11 Harrison TS, Keating GM. CNS Drugs 2005; 19: 65
- 12 Gueiffier A, Mavel S, Lhassani M, Elhakmaoui A, Snoeck R, Andrei G, Chavignon O, Teulade J.-C, Witvrouw M, Balzarini J, De Clercq E, Chapat J.-P. J. Med. Chem. 1998; 41: 5108
- 13 Elhakmaoui A, Gueiffier A, Milhavet J.-C, Blache Y, Chapat J.-P, Chavignon O, Teulade J.-C, Snoeck R, Andrei G, De Clercq E. Bioorg. Med. Chem. Lett. 1994; 4: 1937
- 14 Lacerda RB, de Lima CK. F, da Silva LL, Romeiro NC, Miranda AL. P, Barreiro EJ, Fraga CA. M. Bioorg. Med. Chem. 2009; 17: 74
- 15 Márquez-Flores YK, Campos-Aldrete ME, Salgado-Zamora H, Correa-Basurto J, Meléndez-Camargo ME. Med. Chem. Res. 2012; 21: 3491
- 16 Rival Y, Grassy G, Michel G. Chem. Pharm. Bull. 1992; 40: 1170
- 17 Al-Tel TH, Al-Qawasmeh RA. Eur. J. Med. Chem. 2010; 45: 5848
- 18 Anaflous A, Benchat N, Mimouni M, Abouricha S, Ben-Hadda T, El-Bali B, Hakkou A, Hacht B. Lett. Drug Des. Discov. 2004; 1: 224
- 19 Almirante L, Polo L, Mugnaini A, Provinciali E, Rugarli P, Biancotti A, Gamba A, Murmann W. J. Med. Chem. 1965; 8: 305
- 20 Ribeiro IG, da Silva KC. M, Parrini SC, de Miranda AL. P, Fraga CA. M, Barreiro EJ. Eur. J. Med. Chem. 1998; 33: 225
- 21 Firmansyah D, Ciuciu AI, Hugues V, Blanchard-Desce M, Flamigni L, Gryko DT. Chem. Asian J. 2013; 8: 1279
- 22 Stasyuk AJ, Banasiewicz M, Ventura B, Cyrański MK, Gryko DT. New J. Chem. 2014; 38: 189
- 23 Stasyuk AJ, Banasiewicz M, Cyrański MK, Gryko DT. J. Org. Chem. 2012; 77: 5552
- 24 Bagdi AK, Santra S, Monir K, Hajra A. Chem. Commun. 2015; 51: 1555
- 25 Tyagi V, Khan S, Bajpai V, Gauniyal HM, Kumar B, Chauhan PM. S. J. Org. Chem. 2012; 77: 1414
- 26 Kielesiński Ł, Tasior M, Gryko DT. Org. Chem. Front. 2015; 2: 21
- 27 Hung TQ, Hancker S, Villinger A, Lochbrunner S, Dang TT, Friedrich A, Breitsprecher W, Langer P. Org. Biomol. Chem. 2015; 13: 583
- 28 Hung TQ, Dang TT, Villinger A, Sung TV, Langer P. Org. Biomol. Chem. 2012; 10: 9041
- 29 Banerji B, Chatterjee S, Chandrasekhar K, Ghosh S, Mukherjee K, Mandal C. J. Org. Chem. 2018; 83: 13011
- 30 Pericherla K, Jha A, Khungar B, Kumar A. Org. Lett. 2013; 15: 4304
- 31 Typical Procedure: Preparation of 5-Phenyl-5H-pyrido[2',1':2,3]imidazo[4,5-b]indole (9a) Aniline (40 mg, 0.426 mmol, 1.5 equiv) was added to a pressure tube that was charged with 7 (100 mg, 284 μmol, 1 equiv), Pd2(dba)3 (13 mg, 14 μmol, 0.05 equiv), Xantphos (16 mg, 28 μmol, 0.1 equiv), CuI (5 mg, 28 μmol, 0.1 equiv) and sodium tert-butoxide (164 mg, 1.7 mmol, 6 equiv) under argon. The tube was back-flushed with argon several times. Then, degassed anhydrous toluene (5 mL) was added under argon. The reaction mixture was heated at 110 °C for 12 h. After cooling, the reaction mixture was diluted with dichloromethane (20 mL), and the resulting mixture was filtered through a pad of Celite®, which was washed with dichloromethane (3 x 40 mL). The filtrate was concentrated in vacuo. The crude product was purified by flash chromatography (silica gel; hexane/dichloromethane/ ethyl acetate, 8:1:1) to yield 9a (50 mg, 62%) as a yellowish solid. Mp 168–170 °C. 1H NMR (500 MHz, CDCl3): δ = 8.18–8.13 (m, 1 H), 7.77–7.70 (m, 2 H), 7.68–7.61 (m, 2 H), 7.58–7.55 (m, 1 H), 7.55–7.47 (m, 3 H), 7.33 (dd, J = 6.1, 3.1 Hz, 2 H), 7.11 (ddd, J = 9.3, 6.7, 1.4 Hz, 1 H), 6.70 (td, J = 6.7, 1.2 Hz, 1 H). 13C NMR (126 MHz, CDCl3): δ = 144.62, 141.03, 135.68, 131.37, 129.02, 128.38, 126.80, 125.53, 122.90, 121.40, 120.90, 120.13, 118.72, 117.89, 117.49, 109.90, 109.78. HRMS (ESI): m/z [M + H]+ calcd for C19H13N3: 284.1188; found: 284.1190.